{"id":95516,"date":"2026-01-30T18:30:12","date_gmt":"2026-01-30T18:30:12","guid":{"rendered":"https:\/\/www.europesays.com\/lt\/95516\/"},"modified":"2026-01-30T18:30:12","modified_gmt":"2026-01-30T18:30:12","slug":"vilniuje-bus-gaminama-vakcina-nuo-mirtino-viruso","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/lt\/95516\/","title":{"rendered":"Vilniuje bus gaminama vakcina nuo mirtino viruso"},"content":{"rendered":"\n

\u201eExpreS2ion\u201c pasirinko \u201eNorthway Biotech\u201c kaip gamybos partner\u012f \u012fvertinusi s\u0117kming\u0105 ankstesnio bendradarbiavimo patirt\u012f ir \u012fmon\u0117s kompetencij\u0105 dirbant su specifine \u201eExpreS2\u201c rekombinantini\u0173 baltym\u0173 platforma.\u00a0<\/p>\n

\"1\" <\/a> <\/p>\n

Nipos virusas Indijoje (nuotr. SCANPIX)<\/p>\n

\"2\" <\/a> <\/p>\n

Nipos virusas Indijoje (nuotr. SCANPIX)<\/p>\n

\"3\" <\/a> <\/p>\n

Nipos virusas Indijoje (nuotr. SCANPIX)<\/p>\n

\"4\" <\/a> <\/p>\n

Nipos virusas Indijoje (nuotr. SCANPIX)<\/p>\n

\"5\" <\/a> <\/p>\n

Nipos virusas Indijoje (nuotr. SCANPIX)<\/p>\n

Atsakas \u012f augan\u010di\u0105 sveikatos gr\u0117sm\u0119 <\/p>\n

\u0160i vakcinos gamybos programa yra dalis \u201eExpreS2ion\u201c \u012fgyvendinamo ir Europos<\/a> S\u0105jungos programos \u201eEuropos horizontas\u201c l\u0117\u0161omis finansuojamo projekto \u201eVICI-Disease\u201c. Poreikis operatyviai vystyti vakcin\u0105 tapo itin aktualus Indijoje v\u0117l u\u017efiksavus pavojingo Nipah viruso (NiV) protr\u016bkius. D\u0117l didelio mirtingumo ir specifini\u0173 gydymo priemoni\u0173 tr\u016bkumo \u0161is patogenas laikomas vienu did\u017eiausi\u0173 tarptautini\u0173 sveikatos prioritet\u0173.<\/p>\n

Nipah virusas pasi\u017eymi itin dideliu mirtingumu, siekian\u010diu nuo 40 iki 75 proc., o patvirtint\u0173 vakcin\u0173 \u0161iuo metu n\u0117ra. Virusas sukelia sunkius kv\u0117pavimo tak\u0173 susirgimus bei mirtin\u0105 encefalit\u0105, tod\u0117l jo suvaldymas yra esminis globalaus saugumo u\u017edavinys.<\/p>\n

Nuo technologij\u0173 vystymo iki produkto klinikiniams tyrimams\u00a0 <\/p>\n

\u201eNorthway Biotech\u201c laboratorijose Vilniuje<\/a> bus vykdomas vakcinos gamybos proces\u0173 vystymas bei geros gamybos praktikos standartus atitinkan\u010dios vaistin\u0117s substancijos ir vaistinio produkto gamyba. Veiklas planuojama prad\u0117ti 2026 m. pirm\u0105j\u012f ketvirt\u012f, o gamybos etap\u0105 u\u017ebaigti iki met\u0173 pabaigos.<\/p>\n

Lietuvoje<\/a> gaminamas vakcina gali tapti esminiu l\u016b\u017eiu suvaldant galimas pandemijos gr\u0117smes ateityje. \u0160is bendradarbiavimas dar kart\u0105 patvirtina \u201eNorthway Biotech\u201c paj\u0117gumus teikti auk\u0161\u010diausio lygio biofarmacijos paslaugas ir prisid\u0117ti prie sud\u0117ting\u0173, globali\u0105 reik\u0161m\u0119 turin\u010di\u0173 medicinos sprendim\u0173 \u012fgyvendinimo.<\/p>\n

Kvie\u010diame atrasti nauj\u0105 tv3.lt turin\u012f! Nuo \u0161iol portale j\u016bs\u0173 laukia kasdien nauji testai<\/a> \u2013 i\u0161bandykite savo \u017einias ir smagiai praleiskite laik\u0105. <\/p>\n","protected":false},"excerpt":{"rendered":"\u201eExpreS2ion\u201c pasirinko \u201eNorthway Biotech\u201c kaip gamybos partner\u012f \u012fvertinusi s\u0117kming\u0105 ankstesnio bendradarbiavimo patirt\u012f ir \u012fmon\u0117s kompetencij\u0105 dirbant su specifine…\n","protected":false},"author":2,"featured_media":95517,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[19375,25,30,31,57,43,34,35,55,48,24,54,51,49,50,32,33,37,39,36,38,40,45,23,22,44,28,29,53,42,56,47,26,27,41,46,58,52],"class_list":{"0":"post-95516","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-antrastes","8":"tag-2026-01-29-174500","9":"tag-antrastes","10":"tag-breaking-news","11":"tag-breakingnews","12":"tag-daiktai","13":"tag-dienos-kronika","14":"tag-featured-news","15":"tag-featurednews","16":"tag-gatves-tekstai","17":"tag-gyvenimas","18":"tag-headlines","19":"tag-interneto-pievos","20":"tag-keliones","21":"tag-kultura","22":"tag-laisvalaikis","23":"tag-latest-news","24":"tag-latestnews","25":"tag-lietuva","26":"tag-lietuviu","27":"tag-lithuania","28":"tag-lithuanian","29":"tag-lt","30":"tag-mokslas-ir-it","31":"tag-naujienos","32":"tag-news","33":"tag-pasaulis","34":"tag-populiariausios-naujienos","35":"tag-populiariausiosnaujienos","36":"tag-projektai","37":"tag-rinktiniai-tekstai","38":"tag-simtmecio-portalas","39":"tag-sportas","40":"tag-top-stories","41":"tag-topstories","42":"tag-tv3-lt","43":"tag-verslas","44":"tag-video","45":"tag-zaidimai"},"share_on_mastodon":{"url":"","error":"Validation failed: Text character limit of 500 exceeded"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/posts\/95516","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/comments?post=95516"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/posts\/95516\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/media\/95517"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/media?parent=95516"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/categories?post=95516"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/tags?post=95516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}